University of California, San Francisco: Myelodysplastic Syndromes trials
The registry lists 11 Myelodysplastic Syndromes studies with University of California, San Francisco as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 4Phase 2 4No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell TransplantationCompletedNCT02458235Phase 2Results posted
- A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic MalignanciesCompletedNCT01036009Phase 2Results posted
- Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic DisordersCompletedNCT00301834Phase 2Results posted
- Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT01463046Phase 1
- Unrelated Stem Cell Transplantation for Adults With Hematopoietic DisordersCompletedNCT00511537
- Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00304018Phase 1
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic CancerWithdrawnNCT00301912Phase 2
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerCompletedNCT00296023Not applicable
- Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic AnemiaStatus unknownNCT00295997Not applicable
- Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency DiseaseCompletedNCT00295971Phase 1